Bio-Techne Was Just Bought for $11.3 Billion. Now Comes the Hard Part.

Bio-Techne Was Just Bought for $11.3 Billion. Now Comes the Hard Part.

Last Thursday, many Bio-Techne employees and long-term shareholders woke up wealthier.

Not because they sold anything.

Not because they were paid more.

Simply because someone else decided the company they helped build was worth $11.3 billion.

Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to Bio-Techne’s one-month volume-weighted average trading price. The transaction is expected to close by late 2026 or early 2027, subject to approvals.

Most of the headlines focused on Merck.

I think the more interesting story belongs to the employees.

Your Stock Just Became Real

For years, your RSUs, stock options, and ESPP shares probably existed as numbers on a screen.

You watched them vest.

You watched them fluctuate.

And let’s be honest, the stock has not exactly gone anywhere over the last three years.

Maybe you sold a little.

Maybe you held everything.

Then, overnight, those shares became something different.

Not “potential.”

Not “if the stock goes higher.”

Not “maybe someday.”

Cash.

There is something psychologically different about that transition.

A future possibility suddenly becomes an actual decision.

This Is Where Wealth Is Usually Won—or Lost

You are now starring in a movie that is new to you, but a remake the audience has seen before.

The acquisition isn’t the difficult part.

The six months afterward are.

Uncle Sam has already taken his seat in the theater.

He knows how this movie usually ends.

A lot of smart employees wait too long, underestimate the tax bill, and then discover that liquidity events come with a co-star nobody invited.

How to Give Your Character a Better Ending

Begin with the end in mind.

Find your Han Solo, your Professor X, your person who knows how these stories usually unfold.

Get help early.

Most Bio-Techne employees are smart. That may be the problem.

Smart people often assume they can figure this out on their own.

Some can.

Many wait until tax time, pull their head out of the sand, and discover the monster was sitting there the whole time.

By then, the choices are fewer.

One Final Thought

If you’re a Bio-Techne employee, congratulations.

Moments like this are rare.

But before you celebrate what Merck paid for your company, spend some time thinking about something even more important.

What do you want this money to do for the next 30 years?

Because someday you’ll forget the acquisition price.

You won’t forget what you did with it.